サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1464274

勃起不全の英国市場 - 産業動向と予測（～2031年）

U.K. Erectile Dysfunction Market - Industry Trends and Forecast to 2031
出版日: | 発行: Data Bridge Market Research | ページ情報: 英文 106 Pages | 納期: お問合せ

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
勃起不全の英国市場 - 産業動向と予測（～2031年）
出版日: 2024年03月01日
発行: Data Bridge Market Research
ページ情報: 英文 106 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 図表
  • 目次
概要

英国の勃起不全の市場規模は、2023年の2億6,049万米ドルから2031年までに4億5,163万米ドルに達すると予測され、2024年～2031年の予測期間にCAGRで7.2％の成長が見込まれます。

当レポートでは、英国の勃起不全市場について調査分析し、産業動向と予測、促進要因と抑制要因、企業情勢などの情報を提供しています。

目次

第1章 イントロダクション

第2章 市場セグメンテーション

第3章 エグゼクティブサマリー

第4章 重要考察

  • PESTEL分析
  • ポーターのファイブフォース分析モデル
  • ベンダーシェア分析
  • ブランド分析
    • 主要ブランド
    • ブランドのポジショニング
    • 市場浸透
    • 競合分析
  • 消費者インサイト
    • 人口統計の考察
    • 心理プロファイル
    • 消費者の選好
    • 購買行動
    • 購入決定に影響を与える要因
  • 実績分析
    • 動向の分析
  • 小売分析

第5章 市場の概要

  • 促進要因
    • 慢性疾患の流行
    • 座りがちな生活習慣の増加とそれに伴うストレス
    • 主要市場企業による新製品の発売の増加
    • 病状と投薬に関する患者の意識の高まり
  • 抑制要因
    • 承認に関する規制上の制約
    • 勃起不全治療の高いコスト
  • 機会
    • 処方薬とそのジェネリック医薬品の入手性
    • 技術の進歩の高まり
    • 研究開発の活発化
  • 課題
    • 勃起不全治療薬に伴うさまざまな副作用
    • 熟練した専門家の不足

第6章 英国の勃起不全市場：製品タイプ別

  • 概要
  • 医薬品
    • 経口薬
    • 局所用製剤
    • 陰茎注射
    • 坐薬
  • 機器
    • ペニスポンプ/真空収縮機器
    • 陰茎インプラント
    • 衝撃波療法

第7章 英国の勃起不全市場：タイプ別

  • 概要
  • 二次性勃起不全
  • 原発性勃起不全

第8章 英国の勃起不全市場：年齢層別

  • 概要
  • 40歳未満
  • 40～60歳
  • 60歳以上

第9章 英国の勃起不全市場：エンドユーザー別

  • 概要
  • 病院
  • 専門クリニック
  • 在宅医療
  • 外来手術センター
  • その他

第10章 英国の勃起不全市場：流通チャネル別

  • 概要
  • 直接提供
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第11章 英国の勃起不全市場：企業情勢

  • 企業シェア分析：世界

第12章 SWOT分析

第13章 企業プロファイル

  • PFIZER INC.
  • LUPIN
  • COLOPLAST CORP
  • VIATRIS INC.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • AUGUSTA MEDICAL SYSTEMS
  • BAYER AG
  • BOSTON SCIENTIFIC CORPORATION
  • ELI LILY AND COMPANY
  • RIGICON, INC.
  • ZEPHYR SURGICAL IMPLANTS.

第14章 アンケート

第15章 関連レポート

図表

LIST OF TABLES

  • TABLE 1 U.K. ERECTILE DYSFUNCTION MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION) 56
  • TABLE 2 U.K. DRUGS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 56
  • TABLE 3 U.K. ORAL DRUGS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 56
  • TABLE 4 U.K. BRANDED IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 57
  • TABLE 5 U.K. PENILE INJECTIONS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 58
  • TABLE 6 U.K. DEVICES IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 59
  • TABLE 7 U.K. PENIS PUMPS/VACCUM CONSTRICTION DEVICES IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 59
  • TABLE 8 U.K. PENILE IMPLANTS IN ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 60
  • TABLE 9 U.K. ERECTILE DYSFUNCTION MARKET, BY TYPE, 2022-2031 (USD MILLION) 65
  • TABLE 10 U.K. ERECTILE DYSFUNCTION MARKET, BY AGE GROUP, 2022-2031 (USD MILLION) 70
  • TABLE 11 U.K. ERECTILE DYSFUNCTION MARKET, BY END USER, 2022-2031 (USD MILLION) 75
  • TABLE 12 U.K. ERECTILE DYSFUNCTION MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 80

LIST OF FIGURES

  • FIGURE 1 U.K. ERECTILE DYSFUNCTION MARKET: SEGMENTATION 15
  • FIGURE 2 U.K. ERECTILE DYSFUNCTION MARKET: DATA TRIANGULATION 17
  • FIGURE 3 U.K. ERECTILE DYSFUNCTION MARKET: DROC ANALYSIS 18
  • FIGURE 4 U.K. ERECTILE DYSFUNCTION MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS 19
  • FIGURE 5 U.K. ERECTILE DYSFUNCTION MARKET: COMPANY RESEARCH ANALYSIS 19
  • FIGURE 6 U.K. ERECTILE DYSFUNCTION MARKET: INTERVIEW DEMOGRAPHICS 20
  • FIGURE 7 U.K. ERECTILE DYSFUNCTION MARKET: MARKET END USER COVERAGE GRID 22
  • FIGURE 8 U.K. ERECTILE DYSFUNCTION MARKET: DBMR MARKET POSITION GRID 24
  • FIGURE 9 U.K. ERECTILE DYSFUNCTION MARKET: VENDOR SHARE ANALYSIS 25
  • FIGURE 10 U.K. ERECTILE DYSFUNCTION MARKET: SEGMENTATION 28
  • FIGURE 11 THE RISING RATES OF CHRONIC DISEASES AMONG MEN IS EXPECTED TO DRIVE THE GROWTH OF THE U.K. ERECTILE DYSFUNCTION MARKET FROM 2024 TO 2031 29
  • FIGURE 12 THE DRUGS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE U.K. ERECTILE DYSFUNCTION MARKET IN 2024 AND 2031 29
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF U.K ERECTILE DYSFUNCTION MARKET 45
  • FIGURE 14 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, 2022 53
  • FIGURE 15 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION) 54
  • FIGURE 16 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, CAGR (2024-2031) 54
  • FIGURE 17 U.K. ERECTILE DYSFUNCTION MARKET: BY PRODUCT TYPE, LIFELINE CURVE 55
  • FIGURE 18 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, 2022 62
  • FIGURE 19 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, 2024-2031 (USD MILLION) 63
  • FIGURE 20 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, CAGR (2024-2031) 63
  • FIGURE 21 U.K. ERECTILE DYSFUNCTION MARKET: BY TYPE, LIFELINE CURVE 64
  • FIGURE 22 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, 2022 67
  • FIGURE 23 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, 2024-2031 (USD MILLION) 68
  • FIGURE 24 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, CAGR (2024-2031) 68
  • FIGURE 25 U.K. ERECTILE DYSFUNCTION MARKET: BY AGE GROUP, LIFELINE CURVE 69
  • FIGURE 26 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, 2023 72
  • FIGURE 27 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, 2024-2031 (USD MILLION) 73
  • FIGURE 28 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, CAGR (2024-2031) 73
  • FIGURE 29 U.K. ERECTILE DYSFUNCTION MARKET: BY END USER, LIFELINE CURVE 74
  • FIGURE 30 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, 2022 77
  • FIGURE 31 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 78
  • FIGURE 32 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 78
  • FIGURE 33 U.K. ERECTILE DYSFUNCTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 79
  • FIGURE 34 U.K. ERECTILE DYSFUNCTION MARKET: COMPANY SHARE 2023 (%) 81
目次

U.K. erectile dysfunction market is expected to reach USD 451.63 million by 2031, from USD 260.49 million in 2023 growing at the CAGR of 7.2% in the forecast period of 2024 to 2031.

Market Segmentation

U.K. Erectile Dysfunction Market, By Product Type (Drugs and Devices), Type (Secondary Erectile Dysfunction and Primary Erectile Dysfunction), Age Group (Less than 40, 40-60 and 60 - Above), End User (Hospital, Specialty Clinics, Home Healthcare, Ambulatory Surgical Centers and Others), Distribution Channel (Direct Tenders, Retail Pharmacy, Online Pharmacy, Hospital Pharmacy and Others) - Industry Trends and Forecast to 2031

Overview of U.K. Erectile Dysfunction Market Dynamics

  • Driver
  • Rising prevalence of chronic diseases
  • Restraint
  • Regulatory constraints for approval
  • Opportunity
  • Availability of prescription medication and its generic version

Market Players

Some of the key market players for U.K. erectile dysfunction market are:

  • Lupin
  • Teva Pharmaceutical Industries Ltd.
  • Augusta Medical Systems
  • Boston Scientific Corporation
  • Coloplast Corp
  • Rigicon, Inc.
  • Pfizer Inc.
  • Bayer AG
  • Eli Lily and Company
  • Viatris Inc.
  • ZSI, Zephyr Surgical Implants

TABLE OF CONTENTS

1 INTRODUCTION 11

  • 1.1 OBJECTIVES OF THE STUDY 11
  • 1.2 MARKET DEFINITION 11
  • 1.3 OVERVIEW OF U.K. ERECTILE DYSFUNCTION MARKET 11
  • 1.4 CURRENCY AND PRICING 12
  • 1.5 LIMITATIONS 12
  • 1.6 MARKETS COVERED 13

2 MARKET SEGMENTATION 15

  • 2.1 MARKETS COVERED 15
  • 2.2 GEOGRAPHICAL SCOPE 16
  • 2.3 YEARS CONSIDERED FOR THE STUDY 16
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 17
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 20
  • 2.6 MULTIVARIATE MODELLING 21
  • 2.7 MARKET END USER COVERAGE GRID 22
  • 2.8 PRODUCT LIFELINE CURVE 23
  • 2.9 DBMR MARKET POSITION GRID 24
  • 2.10 VENDOR SHARE ANALYSIS 25
  • 2.11 SECONDARY SOURCES 26
  • 2.12 ASSUMPTIONS 26

3 EXECUTIVE SUMMARY 27

4 PREMIUM INSIGHTS 29

  • 4.1 PESTEL ANALYSIS 30
  • 4.2 PORTER'S FIVE FORCES MODEL 31
  • 4.3 VENDOR SHARE ANALYSIS 32
  • 4.4 BRAND ANALYSIS 33
    • 4.4.1 LEADING BRANDS 33
    • 4.4.2 BRAND POSITIONING 33
    • 4.4.3 MARKET PENETRATION 34
    • 4.4.4 COMPETITIVE ANALYSIS 35
  • 4.5 CONSUMER INSIGHTS 36
    • 4.5.1 DEMOGRAPHIC INSIGHTS 36
    • 4.5.2 PSYCHOGRAPHIC PROFILE 36
    • 4.5.3 CONSUMER PREFERENCES 37
    • 4.5.4 PURCHASING BEHAVIOUR 37
    • 4.5.5 FACTORS INFLUENCING BUYING DECISION 37
  • 4.6 PERFORMANCE ANALYSIS 39
    • 4.6.1 TREND ANALYSIS 39
  • 4.7 RETAIL ANALYSIS 41

5 MARKET OVERVIEW 44

  • 5.1 DRIVERS 46
    • 5.1.1 RISING PREVALENCE OF CHRONIC DISEASES 46
    • 5.1.2 RISING ADOPTION OF SEDENTARY LIFESTYLE AND ASSOCIATED STRESS 46
    • 5.1.3 RISING PRODUCT LAUNCHES BY MAJOR MARKET PLAYERS 47
    • 5.1.4 RISING PATIENT AWARENESS REGARDING THE CONDITION AND MEDICATION 47
  • 5.2 RESTRAINTS 48
    • 5.2.1 REGULATORY CONSTRAINTS FOR APPROVAL 48
    • 5.2.2 HIGH COST OF ERECTILE DYSFUNCTION TREATMENT 48
  • 5.3 OPPORTUNITIES 49
    • 5.3.1 AVAILABILITY OF PRESCRIPTION MEDICATION AND ITS GENERIC VERSION 49
    • 5.3.2 RISING TECHNOLOGICAL ADVANCEMENTS 49
    • 5.3.3 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 50
  • 5.4 CHALLENGES 51
    • 5.4.1 VARIOUS SIDE EFFECTS ASSOCIATED WITH ERECTILE DYSFUNCTION DRUGS 51
    • 5.4.2 LACK OF SKILLED PROFESSIONALS 51

6 U.K. ERECTILE DYSFUNCTION MARKET, BY PRODUCT TYPE 52

  • 6.1 OVERVIEW 53
  • 6.2 DRUGS 56
    • 6.2.1 ORAL DRUGS 56
      • 6.2.1.1 BRANDED 57
        • 6.2.1.1.1 VIAGRA 57
        • 6.2.1.1.2 CIALIS 57
        • 6.2.1.1.3 LEVITRA 57
        • 6.2.1.1.4 AVANAFIL 57
        • 6.2.1.1.5 OTHERS 57
      • 6.2.1.2 GENERIC 57
    • 6.2.2 TOPICAL FORMULATION 58
    • 6.2.3 PENILE INJECTIONS 58
      • 6.2.3.1 PAPAVERINE 58
      • 6.2.3.2 PHENTOLAMINE 58
      • 6.2.3.3 PROSTAGLANDIN E1 (PGE1) 58
    • 6.2.4 SUPPOSITORIES 58
  • 6.3 DEVICES 59
    • 6.3.1 PENIS PUMPS/VACCUM CONSTRICTION DEVICES 59
      • 6.3.1.1 HAND-POWERED 59
      • 6.3.1.2 BATTERY-POWERED PUMP 59
    • 6.3.2 PENILE IMPLANTS 60
      • 6.3.2.1 SEMIRIGID/MALLEABLE 60
      • 6.3.2.2 INFLATABLE 60
    • 6.3.3 SHOCK WAVE THERAPY 60

7 U.K. ERECTILE DYSFUNCTION MARKET, BY TYPE 61

  • 7.1 OVERVIEW 62
  • 7.2 SECONDARY ERECTILE DYSFUNCTION 65
  • 7.3 PRIMARY ERECTILE DYSFUNCTION 65

8 U.K. ERECTILE DYSFUNCTION MARKET, BY AGE GROUP 66

  • 8.1 OVERVIEW 67
  • 8.2 LESS THAN 40 70
  • 8.3 40-60 70
  • 8.4 60 AND ABOVE 70

9 U.K. ERECTILE DYSFUNCTION MARKET, BY END USER 71

  • 9.1 OVERVIEW 72
  • 9.2 HOSPITALS 75
  • 9.3 SPECIALTY CLINICS 75
  • 9.4 HOME HEALTHCARE 75
  • 9.5 AMBULATORY SURGICAL CENTERS 75
  • 9.6 OTHERS 75

10 U.K. ERECTILE DYSFUNCTION MARKET, BY DISTRIBUTION CHANNEL 76

  • 10.1 OVERVIEW 77
  • 10.2 DIRECT TENDERS 80
  • 10.3 HOSPITAL PHARMACY 80
  • 10.4 RETAIL PHARMACY 80
  • 10.5 ONLINE PHARMACY 80
  • 10.6 OTHERS 80

11 U.K. ERECTILE DYSFUNCTION MARKET, COMPANY LANDSCAPE 81

  • 11.1 COMPANY SHARE ANALYSIS: GLOBAL 81

12 SWOT ANALYSIS 82

13 COMPANY PROFILES 83

  • 13.1 PFIZER INC. 83
    • 13.1.1 COMPANY SNAPSHOT 83
    • 13.1.2 REVENUE ANALYSIS 83
    • 13.1.3 PRODUCT PORTFOLIO 84
    • 13.1.4 RECENT DEVELOPMENTS 84
  • 13.2 LUPIN 85
    • 13.2.1 COMPANY SNAPSHOT 85
    • 13.2.2 REVENUE ANALYSIS 85
    • 13.2.3 PRODUCT PORTFOLIO 86
    • 13.2.4 RECENT DEVELOPMENTS 86
  • 13.3 COLOPLAST CORP 87
    • 13.3.1 COMPANY SNAPSHOT 87
    • 13.3.2 REVENUE ANALYSIS 87
    • 13.3.3 PRODUCT PORTFOLIO 88
    • 13.3.4 RECENT DEVELOPMENTS 88
  • 13.4 VIATRIS INC. 89
    • 13.4.1 COMPANY SNAPSHOT 89
    • 13.4.2 REVENUE ANALYSIS 89
    • 13.4.3 PRODUCT PORTFOLIO 90
    • 13.4.4 RECENT DEVELOPMENTS 90
  • 13.5 TEVA PHARMACEUTICAL INDUSTRIES LTD. 91
    • 13.5.1 COMPANY SNAPSHOT 91
    • 13.5.2 REVENUE ANALYSIS 91
    • 13.5.3 PRODUCT PORTFOLIO 92
    • 13.5.4 RECENT DEVELOPMENTS 92
  • 13.6 AUGUSTA MEDICAL SYSTEMS 93
    • 13.6.1 COMPANY SNAPSHOT 93
    • 13.6.2 PRODUCT PORTFOLIO 93
    • 13.6.3 RECENT DEVELOPMENT 93
  • 13.7 BAYER AG 94
    • 13.7.1 COMPANY SNAPSHOT 94
    • 13.7.2 REVENUE ANALYSIS 94
    • 13.7.3 PRODUCT PORTFOLIO 95
    • 13.7.4 RECENT DEVELOPMENTS 95
  • 13.8 BOSTON SCIENTIFIC CORPORATION 96
    • 13.8.1 COMPANY SNAPSHOT 96
    • 13.8.2 REVENUE ANALYSIS 96
    • 13.8.3 PRODUCT PORTFOLIO 97
    • 13.8.4 RECENT DEVELOPMENTS 97
  • 13.9 ELI LILY AND COMPANY
    • 13.9.1 COMPANY SNAPSHOT 98
    • 13.9.2 REVENUE ANALYSIS 98
    • 13.9.3 PRODUCT PORTFOLIO 99
    • 13.9.4 RECENT DEVELOPMENTS 99
  • 13.10 RIGICON, INC. 100
    • 13.10.1 COMPANY SNAPSHOT 100
    • 13.10.2 PRODUCT PORTFOLIO 100
    • 13.10.3 RECENT DEVELOPMENT 101
  • 13.11 ZEPHYR SURGICAL IMPLANTS. 102
    • 13.11.1 COMPANY SNAPSHOT 102
    • 13.11.2 PRODUCT PORTFOLIO 102
    • 13.11.3 RECENT DEVELOPMENT 102

14 QUESTIONNAIRE 103

15 RELATED REPORTS 106